Proteins and Peptides
9 January 2014
Trevena Announces Dosing of First Patient in Phase 2b BLAST-AHF Trial of TRV027 for Acute Heart Failure9 January 2014
DiaMedica Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of DM199 in Type 2 Diabetic Patients9 January 2014
Promedior Attains Patient Enrollment Milestone in Phase 2 Clinical Study of PRM-151 in Myelofibrosis8 January 2014
XTL Biopharmaceuticals In-licenses hCDR1, a Phase 2 Clinical Stage Asset for the Treatment of Lupus8 January 2014
Neumedicines’ Study Shows HemaMax, Not Neupogen (G-CSF), Improves Survival Outcomes Following Lethal Irradiation8 January 2014
Adocia launches phase IIa clinical trial for its ultra-fast acting formulation of analog insulin7 January 2014
ERYTECH Positions Its Lead Product in Solid Tumors and Launches a Phase II Clinical Study in Pancreatic Cancer6 January 2014
Synageva Biopharma™ Provides Clinical Trial Updates with Sebelipase ALFA in LAL Deficiency2 January 2014
NPS Pharmaceuticals Initiates Global Registration Study of Teduglutide in Pediatric Patients with Short Bowel Syndrome25 December 2013
FDA Approves TRETTEN® for the Treatment of Congenital Factor XIII A-Subunit Deficiency23 December 2013
European Medicines Agency Accepts Marketing Authorization Application for Dalbavancin21 December 2013
Eli Lilly and Company and Boehringer Ingelheim announce new drug application filing in the U.S. for new insulin glargine product20 December 2013
Oramed Announces Successful Results from Ex-US Pharmacokinetic Study of its Oral Insulin for the Treatment of Type 1 Diabetes20 December 2013
Novo Nordisk files for regulatory approval of liraglutide19 December 2013
Blaze Bioscience Announces Initiation of First-in-Human Phase 1 Clinical Study of BLZ-10019 December 2013
Baxter Receives FDA Approval of FEIBA [Anti-Inhibitor Coagulant Complex] for Prophylactic Treatment of Hemophilia A&B Patients with Inhibitors17 December 2013
Finox Biotech Announces First Patients Enrolled in Pivotal US Phase III (FIN3002) study for rFSH16 December 2013
BioLineRx Announces Promising Initial Phase 2 Results of Acute Myeloid Leukemia TreatmentNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports